Corden Pharma International

Aeschenvorstadt 71
4051 Basel
Switzerland

Contact WebSite

Article

CordenPharma Expands Peptide Manufacturing Platform in Switzerland

CordenPharma Expands Peptide Manufacturing Platform in Switzerland

Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.

CordenPharma Invests €900 Million in Peptide Platform Expansion

CordenPharma Invests €900 Million in Peptide Platform Expansion

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.